Consensus Elevance Health, Inc.

Equities

ELV

US0367521038

Market Closed - Nyse 04:00:01 2024-04-19 pm EDT 5-day change 1st Jan Change
531.4 USD +1.19% Intraday chart for Elevance Health, Inc. +6.82% +12.69%

Evolution of the average Target Price on Elevance Health, Inc.

Price target over the last 5 years

History of analyst recommendation changes

ddfc489e7192a64b39e19648500.umT5_1LsFq3D4uxpyn_-MHsr7utqNRujJYHD693yDnY.3AG2qQ24eZiKkIE8vDm6ak8avMY_dFXLbdSGiL-aeQzNE8-xMbpa-oyQ3A~b446cd9df1236d2b3f27c5240e60299c
UBS Adjusts Price Target on Elevance Health to $605 From $585, Maintains Buy Rating MT
Bernstein Adjusts Price Target on Elevance Health to $665 From $629 MT
Leerink Partners Adjusts Elevance Health Price Target to $630 From $565 MT
Jefferies & Co Adjusts Elevance Health Price Target to $604 From $602 MT
Goldman Sachs Raises Elevance Health's Price Target to $600 From $578 MT
RBC Lifts Price Target on Elevance Health to $575 From $574, Cites 'Stronger Guidance,' Keeps Outperform Rating MT
Truist Lifts Price Target on Elevance Health to $600 From $580, Notes 'Solid' Q1, 2024 Guidance Boost, Keeps Buy Rating MT
Wells Fargo Adjusts Elevance Health's Price Target to $600 From $557, Maintains Overweight Rating MT
Barclays Adjusts Elevance Health's Price Target to $621 From $584, Maintains Overweight Rating MT
Cantor Fitzgerald Raises Elevance Health Price Target to $600 from $580 MT
Stephens Adjusts Elevance Health's Price Target to $615 From $580 MT
Elevance Health 1Q Revenue Rises, Membership Keeps Declining; Raises Guidance DJ
Zacks Investment Research Adjusts Price Target on Elevance Health to $523 From $537 MT
Wells Fargo Cuts Price Target on Elevance Health to $557 From $561, Maintains Overweight Rating MT
Barclays Starts Elevance Health With Overweight Rating, $584 Price Target MT
Cantor Fitzgerald Adjusts Price Target on Elevance Health to $580 From $547, Maintains Overweight Rating MT
US proposes reimbursement rate for Medicare Advantage 2025 payments RE
RBC Raises Price Target on Elevance Health to $574 From $572 Amid 'Solid End to 2023,' Keeps Outperform Rating MT
JPMorgan Cuts Price Target on Elevance Health to $552 From $569, Maintains Overweight Rating MT
Investors see life through rose-colored glasses Our Logo
ANALYST RECOMMENDATIONS : Air Products & Chemicals, Barclays, Glencore, Mastercard, Walmart... Our Logo
Central bank bonanza! Our Logo
ANALYST RECOMMENDATIONS : AbbVie, AMD, Astrazeneca, HSBC, Live Nation... Our Logo
Nephron Research Adjusts Price Target on Elevance Health to $500 From $493, Maintains Hold Rating MT
Goldman Sachs Adjusts Price Target on Elevance Health to $572 From $558, Maintains Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
531.4 USD
Average target price
595.3 USD
Spread / Average Target
+12.02%
High Price Target
665 USD
Spread / Highest target
+25.14%
Low Price Target
520 USD
Spread / Lowest Target
-2.15%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Elevance Health, Inc.

UBS
Bernstein
Leerink Partners
Jefferies & Co.
Goldman Sachs
RBC Capital Markets
Truist Securities
Wells Fargo Securities
Barclays
Cantor Fitzgerald
Stephens Inc.
Zacks Investment Research
JPMorgan Chase
Nephron Research
Morgan Stanley
Deutsche Bank Securities
TD Cowen
Wolfe Research
Loop Capital
Morningstar
SVB Securities LLC
Credit Suisse
Mizuho Securities
BofA Securities
Cowen
SVB Leerink
Argus
BMO Capital
Seaport Global Securities
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
  1. Stock Market
  2. Equities
  3. ELV Stock
  4. Consensus Elevance Health, Inc.